BDBM221526 US9303045, 10::US9303045, 111::US9695195, 111

SMILES CC(C)S(=O)(=O)n1cc(C(=O)NC2CC3COCC(C2)N3C)c2ccccc12

InChI Key InChIKey=WQOYQHFFLJQYOW-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 221526   

Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221526(US9303045, 10 | US9303045, 111 | US9695195, 111)
Affinity DataIC50:  0.570nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221526(US9303045, 10 | US9303045, 111 | US9695195, 111)
Affinity DataIC50:  0.770nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221526(US9303045, 10 | US9303045, 111 | US9695195, 111)
Affinity DataIC50:  0.570nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221526(US9303045, 10 | US9303045, 111 | US9695195, 111)
Affinity DataIC50:  0.770nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent